Product Information
TOPIRAMATE ER 200 MG CAPSULE is a generic product labeled by Endo USA Inc., priced at $20.3736 per EA under NDC 10370036801. Its NADAC has been published 172 times since Jun 21, 2023.
FDA first approved this application on Mar 1, 2023. Its Orange Book therapeutic-equivalence code is AB1 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
200 mg/1
Manufacturer
Endo USA Inc.NDC
10370036801
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TOPIRAMATEApproval Type
Generic (ANDA)
FDA Application
ANDA205976FDA Approved
3/1/2023
TE Code
AB1
On Market Since
3/24/2023
Pharmacological Classes
Price Statistics
The NADAC for TOPIRAMATE ER 200 MG CAPSULE has been published 172 times since Jun 21, 2023, and over the history we have for it it has declined 39.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $20.3736 per EA |
|---|---|
| All-time high | $34.7626 (Jan 10, 2024) |
| All-time low | $18.7572 (Jul 17, 2024) |
| 52-week high | $25.8176 |
| 52-week low | $20.3736 |
| Median price | $25.4775 |
| Average price | $26.3409 |
| Largest weekly change | +22.6% (Nov 22, 2023) |
| Weeks tracked | 172 |
| Tracking since | Jun 21, 2023 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 53% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Endo USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Topiramate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TOPIRAMATE ER 200 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for TOPIRAMATE ER 200 MG CAPSULE, manufactured by Endo USA Inc., is $20.3736 per EA (NDC 10370036801), effective Sep 30, 2026.
How has the price of TOPIRAMATE ER 200 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for TOPIRAMATE ER 200 MG CAPSULE has declined 39.8%. It has been tracked across 172 weekly CMS publications since Jun 21, 2023.
What are the highest and lowest recorded NADAC prices for TOPIRAMATE ER 200 MG CAPSULE?
Since Jun 21, 2023, the NADAC for TOPIRAMATE ER 200 MG CAPSULE has ranged from a low of $18.7572 (Jul 17, 2024) to a high of $34.7626 (Jan 10, 2024), with a median of $25.4775 per EA.
Are there cheaper alternatives to TOPIRAMATE ER 200 MG CAPSULE?
Yes. 6 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TOPIRAMATE ER 200 MG SPRINK CAP, is $9.5420 per EA — about 53% below TOPIRAMATE ER 200 MG CAPSULE.
Who manufactures TOPIRAMATE ER 200 MG CAPSULE?
TOPIRAMATE ER 200 MG CAPSULE (NDC 10370036801) is labeled by Endo USA Inc., and CMS classifies it as a generic product.